Cancer Advance
Date: Location: Cost:
Thu, Sep 19, 2013 Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Rotunda Room, 3rd Floor
Boston, MA 02115

Starting at $1975


Dress Code:
Business Casual


September 19, 2013

Time Agenda
7:00-8:00 am

Registration and Networking Breakfast

8:00-8:30 am

Welcome and Opening Remarks
Jeffrey Flier, Dean of Harvard Medical School

Perspectives from co-hosts
Julian Adams, Rafael Amado, Jose Baselga, Raju Kucherlapati

8:30-9:00 am

Cancer Treatment: Where Are We Now, Where Are We Headed?
Jose Baselga, Memorial Sloan Kettering; Paul Billings, Life Technologies; Edward Bradley, MedImmune; Robert Wild, Eli Lilly
Moderator: Jerry McMahon, Kolltan Pharmaceuticals

9:00-9:30 am

Oncology Market Outlook
Jeb Keiper, GlaxoSmithKline; Scott Morenstein, Valence Life Sciences; Mina Sooch, ProNAi Therapeutics; Peter Thompson, OrbiMed
Moderator: Mike King, JMP Securities

9:30-10:00 am

Bench to Bedside Keynote: The New Phase I Clinical Trial in Oncology
Jose Baselga
, Memorial Sloan Kettering
Moderated Q&A: Smart Clinical Trial Design In the Era of Personalized Medicine: What Are the Challenges?
Joanna Horobin
, Verastem; Raju Kucherlapati, Harvard Medical School

10:00-10:30 am

Novel Therapeutic Modalities
Elisabet de los Pinos, Aura Biosciences; Hans-Peter Gerber, Pfizer; Dan Haber, MGH Cancer Center; Paul Lammers, Mirna Therapeutics; Saurabh Saha, BioMed Valley Discoveries
Moderator: Edward Garmey, Cerulean Pharma

10:30-11:00 am

Betting On Oncology: Investor Perspectives
Alexis Borisy, Third Rock Ventures; Jean George, Advanced Technology Ventures; Markus Goebel, Novartis Venture Fund; Sara Nayeem, New Enterprise Associates; Jill Wahleithner, Wasatch Advisors
Moderator: Robert Forrester, Verastem

11:00-11:30 am

Personalized Medicine in Oncology
Scott Biller, Agios Pharmaceuticals; Christine Bunt, INTICA Biomedical; Jakob Dupont, OncoMed; Jens Oliver Funk, Principia Biopharma; Markus Warmuth, H3 Biomedicine
Moderator: Mark Pykett, Navidea

11:30-12:00 pm

Bench to Bedside Keynote: The Velcade Story
Julian Adams
, Infinity
Moderated Q&A: Get it Right in Phase 1
Jonathan Pachter, Verastem

12:00-1:00 pm

Networking Lunch
Tables hosted by: Julian Adams, Rafael Amado, Alexis Borisy, Pablo Cagnoni, George Demetri, Robert Forrester, Dan Haber, Raju Kucherlapati, Debasish Roychowdhury, Robert Urban, Bob Weinberg, Christoph Westphal

1:00-1:30 pm

The Importance Of Collaboration: Academia/Industry and Biotech/Pharma Examples
Belén Carrillo-Rivas, Pfizer; Michael Giordano, Bristol-Myers Squibb; Axel Hoos, GlaxoSmithKline; Peter Kosa, Novartis; Kelly Page, Millennium
Moderator: Robert Urban, Johnson & Johnson

1:30-2:00 pm

Regulatory and Reimbursement Pressures For Cancer Drugs: Discussions on Efficacy and Price
Jeffrey Bacha, Del Mar Pharmaceuticals; Pablo Cagnoni, Onyx Pharmaceuticals; Usman Iqbal, Sanofi Oncology; Dan Paterson, Verastem; Collier Smyth, Genentech
Moderator: Steve Stefano, SynopiaRx

2:00-2:30 pm

Bench To Bedside Keynote: Learning from Failure as well as from Success
Debasish Roychowdhury
, Sanofi
Moderated Q&A: The Hallmarks of a Successful Oncology Drug: A Moving Target?
George Demetri
, Dana Farber Cancer Institute

2:30-3:00 pm

Deal Structures: Balancing the Risk
Michael Attar, Celgene; John DeYoung, Pfizer; Walter Ogier, Acetylon; Andrew Weisenfeld, MTS Health Partners
Moderator: Steven Tregay, FORMA Therapeutics

3:00-3:30 pm

Redefining Cancer: Insights from Cancer Stem Cells, Epigenetics and More
Ivan Bergstein, Stemline Therapeutics; Eric Hedrick, Epizyme; Niclas Stiernholm, Stem Cell Therapeutics; Bob Weinberg, Whitehead Institute; Mary Woodall-Jappe, Eisai
Moderator: Michael McCullar, Astex Pharmaceuticals

3:30-4:00 pm

Networking Break

4:00-4:30 pm

The Empowered Patient
Ton Bunt, Izumi Biosciences; Fred Cope, Navidea; Kevin Hrusovsky, Buckeye Growth Partners; Walter Ogier, Acetylon; Peter Ordentlich, Syndax
Moderator: Raju Kucherlapati, Harvard Medical School

4:30-5:00 pm

Bench to Bedside Keynote: Treating Late-Phase Melanoma with MEK Inhibitors: GSK's Trametinib Story
Rafael Amado
, GlaxoSmithKline
Moderated Q&A: Drug Combinations to Tackle Resistance: The Challenge and The Promise
Tim Clackson

5:00-5:30 pm

Cancer in 15 Years: Predictions
Nick Bacopoulos, Mersana; Doug Fambrough, Dicerna; Manfred Lehnert, Millennium; Sean McCarthy, CytomX Therapeutics; Sharon Shacham, Karyopharm Therapeutics
Moderator: Carl Gordon, OrbiMed

5:30-6:00 pm

Bench to Bedside Keynote: Immunotherapy for Cancer Treatment: The Yervoy Story
Nils Lonberg
, Bristol-Myers Squibb
Moderated Q&A: Immunotherapy: A New Paradigm for Cancer Patients
Chad Robins
, Adaptive Biotechnologies

6:00-7:00 pm

Cocktails and Hors d'oeuvres

Sponsored by: